Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Targagenix

Request full access

Novel cancer therapy targeting chemotherapy-resistant tumors

Town of Brookhaven, United StatesBiotech & Life Sciences

About Targagenix

TargaGenix, Inc. is a biotechnology company founded in June 2013 as a spinout from Stony Brook University. The company is focused on developing novel therapies to treat cancer, specifically targeting cancer stem cells and bulk tumor cells that are resistant to existing chemotherapy.

The company's lead product is a third-generation taxane known as DHA-SBT-1214. This compound was the result of over a decade of research led by Dr. Iwao Ojima at Stony Brook University's Institute of Chemical Biology & Drug Discovery to find molecules effective against drug-resistant tumors. The agent has shown promise in preclinical models by eliminating tumors and has been licensed to TargaGenix to advance its development towards clinical use. A key feature is its formulation within a fatty-acid based nanoemulsion, which reduces toxicity and improves how the drug is absorbed and distributed in the body.

The President and CEO is James Egan, who has a background in both academic and commercial drug development and holds a PhD in Molecular Pharmacology from Stony Brook University. The company's business model involves advancing its compounds through clinical trials to gain regulatory approval, with the aim of partnering with larger pharmaceutical firms for commercialization. TargaGenix has received investment to advance its lead compound, NE-DHA-SBT-1214, to market as a potential treatment for colorectal cancer and other solid tumors, with plans to test it as both a standalone drug and in combination with other immuno-oncology agents.

Source: Dealroom company data

Targagenix in the Town of Brookhaven ecosystem

Live from Dealroom

The Targagenix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Accelerate New York Seed Fund
  • AJI Capital

Series A1 investor entered at this stage

  • DeBere Capital Partners

Series B and later1 investor entered at this stage

  • TVM Capital Life Science
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Town of Brookhaven HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Targagenix on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Targagenix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.